Philadelphia Multiple Myeloma Rounds 2021

Dr. Tulin Budak-Alpdogan is an oncologist in Camden, New Jersey and is affiliated with multiple hospitals in the area, including Cooper University Health Care-Camden and Mercy Fitzgerald Hospital. She received her medical degree from Hacettepe University Faculty of Medicine and has been in practice for more than 20 years.

Dr. Cohen received his medical degree and Internal medicine training from the University of Pennsylvania and completed his Hematology/Medical oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York. Board certified in internal medicine, medical oncology, and hematology, Dr. Cohen is a member of ASH, ASCO, AACR and the International Myeloma Society, and a reviewer for a number of peer-reviewed journals. He has written dozens of original articles, book chapters, and reviews on cancer immunotherapy, multiple myeloma, amyloidosis, and stem cell transplant.

Dr. Cohen is currently Director of Myeloma Immunotherapy and an Associate Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania in Philadelphia.

Dr Stadtmauer is Chief of the Hematologic Malignancies Section within the Division of Hematology-Oncology, Department of Medicine of the Perelman School of Medicine, at the University of Pennsylvania in Philadelphia, PA. He is also the Co-Leader of the Abramson Cancer Center Hematologic Malignancies Research Program and the Penn Medicine Hematologic Malignancies Translational Center of Excellence. He has been associated with the University for over 30 years. He was the Co-Chairman of the Bone Marrow Transplant Committee of the NCI funded Eastern Cooperative Oncology Group (ECOG) for ten years and is a member of the Myeloma and Leukemia Core Committees. He has been associated with the Center for International Bone Marrow Transplant Research (CIBMTR) for over a decade with leadership positions including chair of the nominating committee, co-chair Solid Tumor Working Committee and member of the Clinical Trials Advisory Committee. He is also a founding member of the Steering Committee of the NIH sponsored Blood and Marrow Transplant Clinical Trial Network (BMTCTN) and elected to serve as Chairman in 2022. He is also member of the International Myeloma Working Group (IMWG).

Dr. Stadtmauer is widely published on the subjects of multiple myeloma, acute and chronic leukemia, andbone marrow transplantation and CAR T cell therapy. He has been appointed to the editorial boards of the Leukemia, Journal of Clinical Oncology and Bone Marrow Transplantation.  His works have appeared in such premier peer-reviewed journals as the New England Journal of Medicine, Journal of Clinical Oncology, Science, British Journal of Haematology, Blood, Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation, JAMA, Nature Medicine, Lancet Oncology, Science Translational Medicine and Annals of Internal Medicine. He has been a member of the Career Development Award Selection Committee for the Leukemia and Lymphoma Society.His work has ranged from conducting the definitive study of autologous bone marrow transplant for breast cancer to pioneering clinical trials with cellular immunotherapy, CRISPR genetic engineering and vaccination for blood cancers. 

Dr. Stadtmauer graduated with an AB degree with distinction in biochemistry from Cornell University and then completed his MD at the University of Pennsylvania School of Medicine. He served his internship and residency in internal medicine at the Albert Einstein College of Medicine in the Bronx, NY. He completed his Fellowship in Hematology/Oncology at the University of Pennsylvania where he founded the Bone Marrow Transplant Program in 1987 and the Myeloma Program in 1999. He has been awarded the DuPont Guerry, IV, MD Award for Outstanding Mentorship, University of Pennsylvania School of Medicine, the Headstrong Achievement Award for advancement and achievements in the fight against cancer, and the Distinguished Partner in Hope Award for dedication to blood cancers’ research and patient care. His name has appeared for decades in the ‘Best Doctors in America’, ‘Best Doctors in America for Cancer’ and as a ‘Top Doc’ in Philadelphia Magazine.

Patricia A. Mangan, MSN, CRNP, is Nurse Lead of the Hematologic Malignancies and Stem Cell Transplant Programs at the Abramson Cancer Center of the University of

Pennsylvania in Philadelphia. In addition, she works in collaborative practice with Edward A. Stadtmauer, MD, focusing on the care of patients with multiple myeloma and other blood cancers. She is also a Clinical Academic Associate at the University of Pennsylvania’s School of Nursing. Ms. Mangan is a member of the Nursing Leadership Board of the International Myeloma Foundation.

She earned her master of science in nursing degree from the University of Pennsylvania and is a board certified registered nurse practitioner (CRNP) and clinical nurse specialist.

 An invited speaker on a broad number of topics that deal with bone marrow transplant, cellular immunotherapy and the care of patients with hematologic malignancies, Patricia Mangan has lectured on both the local, national and international level. The results of her work have appeared in such peer-reviewed journals as Science, Blood, Nursing, Bone Marrow Transplant, Clinical Journal of the Oncology Nursing Society (CJON), The Lancet Haematology and The Nurse Practioner